For years, the bone-deep exhaustion of treatment-resistant depression (TRD) was dismissed as a secondary symptom of a mood disorder. However, a landmark placebo-controlled clinical trial from the National Institutes of Health (NIH) has revealed a biological reality: depressed brains suffer from a corrupted sleep engine. Using a two-process model of sleep, the researchers focused on "Process S"—the homeostatic sleep drive that builds up chemical pressure (via adenosine) throughout the day. Under normal conditions, this pressure triggers "synaptic downscaling" during deep non-rapid eye movement (NREM) sleep, which behaves like clearing a computer's cache or turning down the background volume on waking connections. In TRD patients, the internal thermostat for this process is broken, leading to a severe deficit in slow-wave activity (SWA), particularly during the crucial first 90-minute cycle of the night (NREM1). This leaves patients waking up feeling like they ran a marathon in their sleep—analogous to a smartphone with corrupted battery software that only ever charges to 10% while background apps drain the system.

The NIH study monitored 91 unmedicated TRD patients and 42 healthy volunteers in a specialized sleep lab using polysomnography. To ensure the validity of Process S, patients were kept awake all day playing board games to prevent them from "bleeding off" sleep pressure through daytime naps. The results were dramatic: a single IV infusion of ketamine (0.5 mg/kg) acted as a hard operating system reboot on the very first night. In patients who responded clinically to ketamine (defined by a 50% or greater drop in depression scores on the MADRS scale), sleep efficiency rose past 87%, total sleep time surpassed 400 minutes, and sleep latency dropped from 30 minutes to under 20. In contrast, healthy volunteers showed no changes due to a "ceiling effect" (their systems were already running optimally), while non-responders' sleep architecture remained broken. Unlike traditional sleep aids that act as chemical off-switches creating "junk sleep" while suppressing deep waves, ketamine functions as a biological system administrator that clears the cache and executes the brain's natural restorative maintenance.

However, the study also revealed a crucial limitation: the sleep-reboot effect diminished with age, especially in older non-responders. Mechanistically, ketamine triggers a glutamate burst that releases brain-derived neurotrophic factor (BDNF). While pop science describes BDNF as "fertilizer for the brain," it is more akin to an aggressive biological construction crew deploying jackhammers to break down rigid, depressed neural pathways and build new dendritic branches. To succeed, this crew needs "plasticity reserve"—the concrete and steel raw materials that naturally decline with age and decades of chronic depression. When the brain has been immobilized in a cast of depressive rigidity for decades, a single infusion is not enough. Rebuilding this reserve requires a sustained protocol resembling physical therapy, such as stacked dosing and behavioral therapies. Ultimately, this breakthrough suggests that consumer sleep wearables could soon replace subjective psychiatric questionnaires by tracking overnight slow-wave recovery, providing doctors with objective biological data confirming if a patient's physical hardware is actively healing by breakfast.

Reference:

Hejazi, N., Kheirkhah, M., Riedner, B., Yuan, Q., Chholak, R., Momenan, R., Jones, G., Goldman, D., & Zarate, C. A., Jr. (2026). Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression. Neuropsychopharmacology. Advance online publication. https://doi.org/10.1038/s41386-026-02465-4